CSE PREV
LAST 0.04
CHANGE -0.01
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.04
CHANGE: -0.01
OTC: PRVCF
FSE: 18H

Nature Identical Peptides from the Caribbean Blue Scorpion Venom to Assist with Cancer-Targeted Treatment

We plan to identify active peptides that are providing the immune boosting, pain relieving, and tumour selective properties, then test what happens when used on various abnormal cells like brain, lung and breast cancers.

A preclinical research and development program is now underway.   It was designed and is being directed by our Chief Science Officer, Dr. Mak Jawadekar, PhD.

PreveCeutical, and partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours. Our initial focus will be on targeting a very aggressive form of brain cancer (glioma). From there we plan to extend the program to screen our library of nature identical peptides in a high throughput screening (HTS) manner across a range of other cancers.

1. PROPRIETARY CHEMISTRY ->

2. LARGE SCALE AUTOMATED SYNTHESIS ->

3. NATURE IDENTICAL PEPTIDES ->

PreveCeutical and Sports 1 Marketing

PreveCeutical signed a joint venture with Sports 1 Marketing. The joint venture was established to develop a therapeutic product geared towards athletes who suffer from concussions (Mild Traumatic Brain Injury).

Through PreveCeutical's current Research and Development program connected to the Caribbean Blue Scorpion venom, PreveCeutical and Sports 1 Marketing believe that there is therapeutic potential in the peptides and proteins to potentially treat concussions.

According to the Centers for Disease Control and Prevention website, a severe concussion not only impacts the life of an individual and their family, but it also has a large societal and economic toll. The estimated economic cost of concussions in 2010, including direct and indirect medical costs, is estimated to be approximately $76.5 billion. Additionally, the cost of fatal concussions requiring hospitalisation, many of which are severe, account for approximately 90% of the total concussion medical costs.

Founded by Hall of Fame Quarterback Warren Moon and veteran sports & technology executive David Meltzer, Sports 1 Marketing is a global sports and entertainment marketing agency that leverages over $20 billion in relationship capital and over 38 years of business experience, bringing athletes, celebrities and businesses together to make a lot of money, help a lot of people, and have a lot of fun.

 

Sports 1 Marketing

Sign up for the latest news and updates